The U.S. Food and Drug Administration (US FDA) recently approved Biocon Biologics’ first-to-file application for Yesafili™ (aflibercept-jbvf), which is intended for the treatment of age-related macular degeneration and visual impairment. It was the Company’s expansion into the ophthalmology therapeutic area in the United States. --- FDA-approved biosimilars are safe and effective treatment options that could provide immense savings on lifesaving medications. Learn more on the @FDA’s website here: https://lnkd.in/dHZFzaq
FDA-approved biosimilars are safe and effective treatment options that could provide immense savings on lifesaving medications. Learn more on the FDA's website here: https://lnkd.in/dHZFzaq